Yangtze River Pharmaceutical Group and Shanghai Haiyan Pharmaceutical Technology have discovered substituted pyrazolo[1,5-a]pyrimidine-7-amine derivatives acting as cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer.